All eyes on Novo's new outlook on eve of 2021 report
On Wednesday morning, when Novo Nordisk presents its full-year financial results prior to the stock exchange opening, the attention of analysts and investors will be on the outlook for the new year, as growth isn’t expected to match 2021 levels due to production issues with obesity drug Wegovy.
by marketwire, translated by daniel pedersen
All eyes will be fixed on Novo Nordisk’s 2022 guidance when the company publicizes its full-year report on Wednesday morning.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Production issues could put a damper on Novo Nordisk's 2022
For subscribers
